A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Aim of the study is to compare efficacy and safety of YM177 with placebo and etodolac in patients with postoperative pain.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Celecoxib; Etodolac

Criteria

Inclusion Criteria:

• Patients with spontaneous pain within 24 hours postoperatively

• The intensity of the pain:

• 4-categorical assessment: "Moderate pain" or "Severe pain"

• VAS assessment: 45.0 mm or higher

• Patients whose postoperative pain can be managed using an oral NSAID

Exclusion Criteria:

• A past history of aspirin-induced asthma

• A past of ischemic heart disease, serious arrhythmia, congestive heart failure or cerebrovascular disease

• Patients who undergoes the surgical procedure under general anesthesia

• Patients taking excluded medications